CIK 0001858848
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Tenaya Therapeutics, Inc.
Sign in to watch- Ticker
- TNYA
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 813789973
- Phone
- +1 415-865-2066
- Business address
- 171 OYSTER POINT BLVD., SUITE 500, SOUTH SAN FRANCISCO, CA, 94080
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-10 | Ali Faraz Chief Executive Officer | Sale | −3,947 | $0.54 | $2K | 320,514 |
| 2025-03-05 | COLUMN GROUP III GP, LP 10% owner | Purchase | +35,714,284 | $0.70 | $25.0M | 49,313,559 |
| 2025-03-05 | COLUMN GROUP III GP, LP 10% owner | Purchase · Series A Warrant (right to buy) | +35,714,284 | 35,714,284 | ||
| 2025-03-05 | COLUMN GROUP III GP, LP 10% owner | Purchase · Series B Warrant (right to buy) | +17,857,142 | 17,857,142 | ||
| 2025-03-05 | GOEDDEL DAVID V Director | Purchase | +35,714,284 | $0.70 | $25.0M | 49,313,559 |
| 2025-03-05 | GOEDDEL DAVID V Director | Purchase · Series A Warrant (right to buy) | +35,714,284 | 35,714,284 | ||
| 2025-03-05 | GOEDDEL DAVID V Director | Purchase · Series B Warrant (right to buy) | +17,857,142 | 17,857,142 | ||
| 2025-02-06 | Ali Faraz Chief Executive Officer | Grant or award | +107,500 | 295,831 | ||
| 2025-02-06 | Ali Faraz Chief Executive Officer | Grant or award | +34,424 | 330,255 | ||
| 2025-02-06 | Ali Faraz Chief Executive Officer | Grant or award · Stock Option (Right to buy) | +650,000 | 650,000 | ||
| 2025-02-06 | Ali Faraz Chief Executive Officer | Returned to the company · Stock Option (Right to Buy) | −353,271 | 0 | ||
| 2025-02-06 | Ali Faraz Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +353,271 | 353,271 | ||
| 2025-02-06 | Ali Faraz Chief Executive Officer | Returned to the company · Stock Option (Right to Buy) | −161,214 | 0 | ||
| 2025-02-06 | Ali Faraz Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +161,214 | 161,214 | ||
| 2025-02-06 | Ali Faraz Chief Executive Officer | Returned to the company · Stock Option (Right to Buy) | −401,390 | 0 | ||
| 2025-02-06 | Ali Faraz Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +401,390 | 401,390 | ||
| 2025-01-24 | Tingley Whittemore Chief Medical Officer | Grant or award | +40,000 | 147,106 | ||
| 2025-01-24 | Tingley Whittemore Chief Medical Officer | Grant or award | +31,676 | 178,782 | ||
| 2025-01-24 | Tingley Whittemore Chief Medical Officer | Grant or award · Stock Option (Right to buy) | +235,000 | 235,000 | ||
| 2025-01-24 | Tingley Whittemore Chief Medical Officer | Returned to the company · Stock Option (Right to Buy) | −69,982 | 0 |
Page 5 of 12 · 228 trades